{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:55:10Z","timestamp":1793994910628,"version":"4.8.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016304","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eprac.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T23:33:10Z","timestamp":1755905590000},"page":"118-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anaplastic Thyroid Carcinoma: A Contemporary Review of Challenges and Advances"],"prefix":"10.1016","volume":"32","author":[{"given":"Amanda","family":"Silver Karcioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Slough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symone V.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mac","family":"Kenzie J Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisheila Gloria","family":"Kinua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Goli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Bible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok R.","family":"Shaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Urken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Zafereo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Abdelhamid Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.eprac.2025.08.009_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib3","article-title":"Clinical trials in management of anaplastic thyroid carcinoma; progressions and set backs: a systematic review","volume":"17","author":"Salehian","year":"2019","journal-title":"Int J Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cncy.22519","article-title":"The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): update on the 2021 ATA ATC guidelines","volume":"130","author":"Silver Karcioglu","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.009_bib8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.5306\/wjco.v14.i12.570","article-title":"Update on current diagnosis and management of anaplastic thyroid carcinoma","volume":"14","author":"Pavlidis","year":"2023","journal-title":"World J Clin Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib9","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/PAS.0000000000002284","article-title":"PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study","volume":"48","author":"Agarwal","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4103\/jcrt.jcrt_1471_22","article-title":"PD-L1 expression in rare and aggressive thyroid cancers: a preliminary investigation for a role of immunotherapy","volume":"19","author":"Boruah","year":"2023","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.009_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib12","first-page":"5888","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.eprac.2025.08.009_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canep.2018.05.009","article-title":"Trends in thyroid cancer: retrospective analysis of incidence and survival in Denmark 1980-2014","volume":"55","author":"Mirian","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.wjorl.2018.05.006","article-title":"Is the incidence of anaplastic thyroid cancer increasing: a population based epidemiology study","volume":"5","author":"Janz","year":"2019","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-20-0080","article-title":"Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in The Netherlands over 3 decades","volume":"183","author":"de Ridder","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol R Coll Radiol"},{"key":"10.1016\/j.eprac.2025.08.009_bib17","series-title":"Practical Management of Thyroid Cancer","first-page":"403","article-title":"Management of anaplastic thyroid cancer","author":"Tennvall","year":"2006"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hed.24784","article-title":"Facilitating anaplastic thyroid cancer specialized treatment: a model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer","volume":"39","author":"Cabanillas","year":"2017","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.009_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaoto.2022.5045","article-title":"Association of treatment strategies and tumor characteristics with overall survival among patients with anaplastic thyroid cancer: a single-institution 21-year experience","volume":"149","author":"Wu","year":"2023","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3174\/ajnr.A5487","article-title":"Imaging of anaplastic thyroid carcinoma","volume":"39","author":"Ahmed","year":"2018","journal-title":"Am J Neuroradiol"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MOO.0000000000000619","article-title":"Airway management, symptom relief and best supportive care in anaplastic thyroid cancer","volume":"28","author":"Moyer","year":"2020","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.009_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ajcp\/aqab159","article-title":"Anaplastic thyroid carcinoma: cytomorphologic features on fine-needle aspiration and associated diagnostic challenges","volume":"157","author":"Podany","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eprac.2025.08.009_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/790834","article-title":"Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer","volume":"2014","author":"Ragazzi","year":"2014","journal-title":"Int J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2025.08.009_bib26","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hed.24559","article-title":"Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012","volume":"39","author":"Baek","year":"2017","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00423-004-0524-5","article-title":"Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients","volume":"390","author":"Besic","year":"2005","journal-title":"Langenbecks Arch Surg"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s002689900610","article-title":"Anaplastic thyroid carcinoma survival","volume":"23","author":"Voutilainen","year":"1999","journal-title":"World J Surg"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib30","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.20936","article-title":"Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors","volume":"103","author":"Kebebew","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.009_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hed.20578","article-title":"Prognostic factors for Korean patients with anaplastic thyroid carcinoma","volume":"29","author":"Kim","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.eprac.2025.08.009_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/hed.27735","article-title":"Neoadjuvant therapy to improve resectability of advanced thyroid cancer: a real-world experience","author":"Russell","year":"2024","journal-title":"Head Neck"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1089\/thy.2023.0136","article-title":"Return of vocal fold motion and surgical preservation of invaded recurrent laryngeal nerves after the use of neoadjuvant therapy in patients presenting with advanced thyroid cancer and vocal fold paralysis: the lazarus effect","volume":"33","author":"Silver Karcioglu","year":"2023","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.009_bib34","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/thy.2023.0201","article-title":"Combination BRAF V600E inhibition with the multitargeting tyrosine kinase inhibitor Axitinib shows additive anticancer activity in BRAF V600E -mutant anaplastic thyroid cancer","volume":"33","author":"Gunda","year":"2023","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib36","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib37","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1089\/thy.2016.0621","article-title":"Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma","volume":"27","author":"Ito","year":"2017","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib38","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.08.009_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.009_bib40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.009_bib42","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib43","first-page":"698","article-title":"Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial","volume":"102","author":"Schneider","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib44","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2007.0120","article-title":"A phase II study of gefitinib in patients with advanced thyroid cancer","volume":"18","author":"Pennell","year":"2008","journal-title":"Thyroid"},{"issue":"29","key":"10.1016\/j.eprac.2025.08.009_bib46","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.009_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/thy.2008.0321","article-title":"A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome","volume":"19","author":"Mooney","year":"2009","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2013.0078","article-title":"Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma","volume":"24","author":"Sosa","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/thy.2022.0050","article-title":"A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer","volume":"32","author":"Lee","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2025.08.009_bib50","article-title":"A phase I\/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma","author":"Sehgal","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(22)00763-X","article-title":"Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG\/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial","volume":"24","author":"Sherman","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib52","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/cancers11070943","article-title":"A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer","volume":"11","author":"Ljubas","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib53","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"187","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"16_suppl","key":"10.1016\/j.eprac.2025.08.009_bib54","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1200\/JCO.2024.42.16_suppl.6095","article-title":"Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)","volume":"42","author":"Cabanillas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib55","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2025.08.009_bib56","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.009_bib57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/ERC-20-0106","article-title":"Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview","volume":"28","author":"Sparano","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"23","key":"10.1016\/j.eprac.2025.08.009_bib60","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.009_bib61","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/cncr.22203","article-title":"Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens","volume":"107","author":"Wang","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.eprac.2025.08.009_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8218949","article-title":"Treatment outcomes in anaplastic thyroid cancer","volume":"2019","author":"Corrigan","year":"2019","journal-title":"J Thyroid Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-8140(01)00382-6","article-title":"Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland","volume":"60","author":"Nutting","year":"2001","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.08.009_bib64","first-page":"E2083","article-title":"Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival","volume":"38","author":"Glaser","year":"2016","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib65","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/cncr.32548","article-title":"Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer","volume":"126","author":"Fan","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.009_bib66","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in response to multimodal therapy in anaplastic thyroid cancer","volume":"102","author":"Prasongsook","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.009_bib67","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hed.21257","article-title":"Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy","volume":"32","author":"Bhatia","year":"2010","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.009_bib68","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/cncr.30493","article-title":"Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base","volume":"123","author":"Pezzi","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13014-023-02249-w","article-title":"Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years","volume":"18","author":"Jacob","year":"2023","journal-title":"Radiat Oncol Lond Engl"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.009_bib70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12020-022-03085-w","article-title":"Risk stratification in patients with anaplastic thyroid carcinoma: role of age","volume":"77","author":"Wang","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.009_bib71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.009_bib72","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/thy.2023.0164","article-title":"Factors associated with survival in anaplastic thyroid carcinoma: a multicenter study from the ENDOCAN-TUTHYREF Network","volume":"33","author":"Jannin","year":"2023","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25010043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25010043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:51:55Z","timestamp":1777618315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25010043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1530891X25010043"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.08.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anaplastic Thyroid Carcinoma: A Contemporary Review of Challenges and Advances","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}